Clinicopathological Features and Prognostic Factors in Patients with Small Bowel Adenocarcinoma

Abstract

Objective:Small bowel adenocarcinoma is a rare tumor, and data on prognosis are limited. We aimed to evaluate the clinicopathological features and prognostic factors in small bowel adenocarcinoma in this study.Method:Twenty-two patients were evaluated. Clinicopathological features and treatment approaches were retrospectively recorded. The Kaplan-Meier and Cox regression analyses were used to assess overall survival and prognostic factors.Results:The origin sites of the tumor were the duodenum (50%), jejunum (31.8%), and ileum (18.2%), respectively. The number of de novo metastatic patients was 11 (50%). The most common metastatic sites were the peritoneum (%45), liver (%41), and lymph nodes (18%). The median overall survival was 19.9 months (7.3-32.5). One- and two-year survival ratios were 65.9% and 39%, respectively. The response ratio (complete or partial) of first-line chemotherapy in metastatic patients was determined as 46.2%. In multivariate analysis, surgery (p=0.024) and age at diagnosis (p=0.017) were statistically significant prognostic factors for overall survival. However, the site of the tumor (p=0.106), de novo metastatic disease (p=0.323), and the number of metastatic sites (p=0.086) were not.Conclusion:Patients with small bowel adenocarcinoma were diagnosed in advanced stages, and the prognosis of the disease was poor. We observed that removing the primary tumor improved survival, and being older than 60 years was a negative prognostic factor.

Keywords

• chemotherapy
• prognosis
• small bowel adenocarcinoma